Additionally OVCXCR2 increased CCL2, probably resulting from a CXCR2-mediated NF-B activation on B sites in the CCL2 promoter[5]

Additionally OVCXCR2 increased CCL2, probably resulting from a CXCR2-mediated NF-B activation on B sites in the CCL2 promoter[5]. CXCL1 added to CXCR2 positive cells led to an increased activation of IB. CXCL1 also led to a significantly greater number of invasive cells in CXCR2 transfected cells, which was blocked by the NF-B inhibitor, Bay 11-7082. In addition, enhanced cell proliferation in CXCR2 positive cells was more sensitive to CXCL1 antibody or an NF-B inhibitor. Finally, CXCR2 transfection of parental cells increased CXCL1 promoter activity via an NF-B site. Thus augmentation of proinflammatory chemokines CXCL1/2, by potentiating NF-B activation through EGFR-transactivated Akt, contributes to CXCR2-driven ovarian cancer progression. == Introduction == Ovarian cancer, one of several inflammation-associated cancers, is the fifth leading cause of cancer death among women. It is an insidious disease because it is typically asymptomatic Thymosin β4 until tumors have spread far beyond the ovaries[1]. The proinflammatory tumor microenvironment of ovarian cancer is clinically associated with peritoneal tumor dissemination and massive ascites, followed by a high mortality rate. Ovarian cancer cells express high levels of tumor necrosis factor (TNF), indicating the potential importance of TNF as a regulator of the proinflammatory tumor microenvironment in this malignancy[2][4]. Particularly, TNF has been shown to regulate chemokine networks in ovarian cancer cells through the nuclear factor-B (NF-B) signaling pathway[5][6]. Chemokines can be critical mediators in a tumor microenvironment by contributing to cancer progression and metastasis[7][8]. Among chemokine receptors, ovarian cancer cells frequently express CXCR2, which has prompted ovarian cancer progression[9]. CXCR2 is also highly expressed in certain other cancer cell types such as lung adenocarcinoma[10], laryngeal squamous cell carcinoma[11], endometrial carcinoma[12], rectal cancer[13], hepatocellular carcinoma[14]and gastric cancer[15]. Because of this association, it may be able to serve as an independent prognostic marker. Thus CXCR2 knockout mice have a significantly reduced tumor burden in prostate cancer[16], murine Lewis lung cancer[17]and renal tumor models[18]when compared to CXCR2 wild-type mice. In addition, a CXCR2 deficiency profoundly suppressed inflammation-driven tumorigenesis in skin and intestine[19]. The absence of CXCR2 in the tumor microenvironment also prevented colon cancer cell growth[20]. Finally, CXCL1, a CXCR2 ligand, was inversely associated with recurrence-free survival in colorectal cancer patients[21]. These facts indicate that a CXCR2-mediated signaling pathway is closely associated with cancer progression. Though multiple pathways such as apoptosis, EGFR activation and angiogenesis are Thymosin β4 involved in CXCR2-mediated signaling[9],[16][20], there is still a big gap on molecular mechanisms linking between CXCR2 and its multiple pathways. In our previous study, ovarian cancer cell lines highly expressed CXCL1-3 and CXCL8[5][6]which all have a high affinity for CXCR2[22]. Even though these CXCR2 ligands are tightly regulated by NF-B signaling[5],[23], it is unclear how CXCR2 and NF-B are mechanically involved in ovarian cancer progression. Here we used Thymosin β4 parental ovarian cancer cell lines and generated stable CXCR2 transfected cells as well as control cells transfected with empty vector. We then defined the impact of NF-B signaling, a main proinflammatory pathway, on the potential contribution of CXCR2 to ovarian cancer progression. == Materials and Methods == == Reagents == Recombinant human TNF, CXCL1 and a CXCL1/2/3 pan specific Thymosin β4 antibody for neutralization were obtained from R&D Systems (Minneapolis, MN). A human CXCL1/2 ELISA kit was purchased from PeproTech (Rocky Hill, NJ). PD98059 was purchased from EMD Chemicals Inc. (Gibbstown, NJ), AG-1478 was from Enzo Life Sciences International, Inc., (Plymouth Meeting, PA) and Bay11-7082 and LY294002 from Cayman Chemical (Ann Arbor, MI). Antibodies were purchased as follows: CXCR2 (E-2, sc-7304) and -actin were from Santa Cruz Biotechnology (Santa Cruz, CA) and IB, IKK, EGFR, Erk1/2, Akt and their Mouse monoclonal to CRTC2 phosphorylated forms, such as IB (Ser32/36), EGFR (Tyr1173), Erk1/2 (Thr202/Tyr204), IKK (Ser176/180) and Akt (Ser473), were from Cell Signaling Technology (Beverly, MA). Lipofectamine 2000, G418 and all liquid culture media were acquired from Invitrogen (Grand Island,.